CAJ | 학술논문

　　目的：探讨DCCIK治疗对Ⅰ期NSCLC术后患者外周血免疫细胞表型的影响。方法：42例经根治手术治疗的肺癌患者,术后TNM分期为Ⅰa期25例,Ⅰb期(低危)17例。22例患者术后经DCCIK治疗两个疗程,在治疗前及治疗后对患者采血检测T细胞亚群(CD3、CD4、CD8)、B细胞(CD19)、NK细胞(CD16+56),余20例患者作为对照组,在观察前及观察后采血检测。结果：未经DCCIK治疗的患者观察后CD3、CD4、CD4/CD8均有升高,CD8、CD19、CD16+56降低,但无统计学意义(P>0.05)。经DCCIK治疗后的患者,CD16+56显著升高(P<0.01),CD3、CD4/CD8比值和CD19在治疗后有升高,但无统计学意义(P>0.05)。结论：DCCIK治疗能增强Ⅰ期NSCLC术后患者机体的细胞免疫功能。
　　목적：탐토DCCIK치료대Ⅰ기NSCLC술후환자외주혈면역세포표형적영향。방법：42례경근치수술치료적폐암환자,술후TNM분기위Ⅰa기25례,Ⅰb기(저위)17례。22례환자술후경DCCIK치료량개료정,재치료전급치료후대환자채혈검측T세포아군(CD3、CD4、CD8)、B세포(CD19)、NK세포(CD16+56),여20례환자작위대조조,재관찰전급관찰후채혈검측。결과：미경DCCIK치료적환자관찰후CD3、CD4、CD4/CD8균유승고,CD8、CD19、CD16+56강저,단무통계학의의(P>0.05)。경DCCIK치료후적환자,CD16+56현저승고(P<0.01),CD3、CD4/CD8비치화CD19재치료후유승고,단무통계학의의(P>0.05)。결론：DCCIK치료능증강Ⅰ기NSCLC술후환자궤체적세포면역공능。
Objective:To investigate effect of dendritic cells with cytokine-induced killer( DCCIK )on the lymphocytes immunophenotype in postoperative patients with stage I non-small cell lung cancer(NSCLC).Methods:42 patients with lung cancer treated by radical surgery, were staged by TNM staging criterion,including stage Ia 25 cases,stage Ib(low risk) 17 cases.22 cases were treated by two course of DCCIK after operation.The T cell subsets、B cell and NK cell in peripheral blood were detected before and after treatment.Other 20 cases were as control group.Results:Although the CD3、CD4、CD4/CD8 were increased and the CD8、CD19、CD16+56 were decreased in patients of control group,there was no difference(P>0.05). After treatment by DCCIK,there was difference of the increasing of CD16+56(P<0.01).Although the CD3、CD4、CD4/CD8 and CD19 were increased after treatment, there was no difference(P>0.05).Conclusion:The cell immunological function of postoperative patients with stage I NSCLC can be enhanced by DCCIK treatment.